Department of Surgery, Division of Trauma, Emergency Surgery and Surgical Critical Care, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
Adv Exp Med Biol. 2012;710:107-33. doi: 10.1007/978-1-4419-5638-5_11.
Shock, regardless of etiology, is characterized by decreased tissue perfusion resulting in cell death, organ dysfunction, and poor survival. Current therapies largely focus on restoring tissue perfusion through resuscitation but have failed to address the specific cellular dysfunction caused by shock. Acetylation is rapidly emerging as a key mechanism that regulates the expression of numerous genes (epigenetic modulation through activation of nuclear histone proteins), as well as functions of multiple cytoplasmic proteins involved in key cellular functions such as cell survival, repair/healing, signaling, and proliferation. Cellular acetylation can be increased immediately through the administration of histone deacetylase inhibitors (HDACI). A series of studies have been performed using: (1) cultured cells; (2) single-organ ischemia-reperfusion injury models; (3) rodent models of lethal septic and hemorrhagic shock; (4) swine models of lethal hemorrhagic shock and multi-organ trauma; and (5) tissues from severely injured trauma patients, to fully characterize the changes in acetylation that occur following lethal insults and in response to treatment with HDACI. These data demonstrate that: (1) shock causes a decrease in acetylation of nuclear and cytoplasmic proteins; (2) hypoacetylation can be rapidly reversed through the administration of HDACI; (3) normalization of acetylation prevents cell death, decreases inflammation, attenuates activation of pro-apoptotic pathways, and augments pro-survival pathways; (4) the effect of HDACI significantly improves survival in lethal models of septic shock, hemorrhagic shock, and complex poly-trauma without need for conventional fluid resuscitation or blood transfusion; and (5) improvement in survival is not due to better resuscitation but due to an enhanced ability of cells to tolerate lethal insults.As different models of hemorrhagic or septic shock have specific strengths and limitations, this chapter will summarize our attempts to create "pro-survival and anti-inflammatory phenotype" in various models of hemorrhagic shock and septic shock.
无论病因如何,休克的特征都是组织灌注减少,导致细胞死亡、器官功能障碍和预后不良。目前的治疗方法主要集中在通过复苏来恢复组织灌注,但未能解决休克引起的特定细胞功能障碍。乙酰化作为一种关键机制,迅速成为调节许多基因表达(通过激活核组蛋白蛋白的表观遗传调节)以及参与关键细胞功能的多种细胞质蛋白功能的关键机制,这些功能包括细胞存活、修复/愈合、信号转导和增殖。细胞乙酰化可以通过给予组蛋白去乙酰化酶抑制剂(HDACI)立即增加。已经进行了一系列研究,使用:(1)培养细胞;(2)单一器官缺血再灌注损伤模型;(3)致死性脓毒症和失血性休克的啮齿动物模型;(4)致死性失血性休克和多器官创伤的猪模型;以及(5)严重创伤患者的组织,以充分描述致命损伤后发生的乙酰化变化以及对 HDACI 治疗的反应。这些数据表明:(1)休克导致核和细胞质蛋白的乙酰化减少;(2)通过给予 HDACI 可以迅速逆转低乙酰化;(3)乙酰化的正常化可防止细胞死亡,减少炎症,减弱促凋亡途径的激活,并增强促存活途径;(4)HDACI 在致死性脓毒症休克、失血性休克和复杂多发伤的模型中显著提高了生存率,而无需常规液体复苏或输血;(5)生存率的提高不是由于更好的复苏,而是由于细胞耐受致命损伤的能力增强。由于不同的失血性或脓毒性休克模型具有特定的优势和局限性,本章将总结我们在各种失血性休克和脓毒性休克模型中尝试创造“抗细胞凋亡和抗炎表型”的努力。